Xeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase – What’s Next?

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) saw strong trading volume on Friday . 4,159,031 shares changed hands during mid-day trading, an increase of 93% from the previous session’s volume of 2,159,568 shares.The stock last traded at $4.88 and had previously closed at $4.56.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on XERS. Piper Sandler reissued a “neutral” rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum lifted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. Jefferies Financial Group restated a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.92.

Xeris Biopharma Stock Performance

The company has a 50-day moving average of $3.64 and a 200 day moving average of $3.29. The firm has a market cap of $742.76 million, a P/E ratio of -10.77 and a beta of 2.32.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mackenzie Financial Corp lifted its holdings in Xeris Biopharma by 446.0% during the 4th quarter. Mackenzie Financial Corp now owns 129,952 shares of the company’s stock valued at $441,000 after purchasing an additional 106,153 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Xeris Biopharma by 118.2% during the fourth quarter. Squarepoint Ops LLC now owns 40,769 shares of the company’s stock worth $138,000 after buying an additional 22,084 shares in the last quarter. Two Sigma Advisers LP acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $47,000. Stonepine Capital Management LLC bought a new stake in Xeris Biopharma during the 4th quarter worth approximately $618,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Xeris Biopharma during the 4th quarter valued at $79,000. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.